Zevalin for Follicular Non-Hodgkin’s Lymphoma

ZevalinIbritumomab tiuxetan (Zevalin, Spectrum) has been approved for patients with previously untreated follicular non-Hodgkin’s lymphoma (NHL) who have achieved a partial or complete response to first-line chemotherapy. This recent indication supplements the drug’s 2002 approval as a therapy for patients with relapsed or refractory low-grade or follicular B-cell NHL. This agent is a CD20-directed radiotherapeutic antibody.

Source: FDA, The Medical News, September 5, 2009